Phibro Animal Health - PAHC Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $22.50
  • Forecasted Upside: 22.95 %
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$18.30
▼ -0.15 (-0.81%)

This chart shows the closing price for PAHC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Phibro Animal Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PAHC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PAHC

Analyst Price Target is $22.50
▲ +22.95% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Phibro Animal Health in the last 3 months. The average price target is $22.50, with a high forecast of $23.00 and a low forecast of $22.00. The average price target represents a 22.95% upside from the last price of $18.30.

This chart shows the closing price for PAHC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 2 investment analysts is to hold stock in Phibro Animal Health. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
8/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
11/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
2/19/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
5/20/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
7/19/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
8/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/25/2022BarclaysDowngradeEqual Weight ➝ Underweight$22.00Low
1/10/2022BarclaysUpgradeUnderweight ➝ Equal Weight$23.00High
11/18/2021Morgan StanleyInitiated CoverageEqual Weight$23.00Low
7/7/2021BarclaysDowngradeEqual Weight ➝ Underweight$23.00High
5/13/2021Morgan StanleyBoost TargetUnderweight$19.00 ➝ $22.00Low
8/6/2020Morgan StanleyDowngradeEqual Weight ➝ Underweight$20.00High
5/8/2020Credit Suisse GroupLower TargetNeutral$25.00 ➝ $23.00Low
3/31/2020G.ResearchUpgradeHold ➝ BuyMedium
2/6/2020G.ResearchDowngradeBuy ➝ HoldLow
2/6/2020GabelliDowngradeBuy ➝ Hold$30.00Low
1/28/2020BarclaysUpgradeUnderweight ➝ Equal Weight$23.00High
9/5/2019Morgan StanleyUpgradeUnderweight ➝ Equal$21.00 ➝ $30.00Medium
8/29/2019Bank of AmericaLower TargetUnderperform$29.00 ➝ $18.00High
8/29/2019BarclaysLower TargetUnderweight$25.00 ➝ $18.00High
8/28/2019Credit Suisse GroupReiterated RatingNeutral$31.00 ➝ $25.00High
6/11/2019BarclaysInitiated CoverageUnderweight ➝ Underweight$25.00High
5/23/2019GuggenheimInitiated CoverageNeutral ➝ NeutralMedium
5/8/2019GabelliUpgradeHold ➝ Buy$42.00Medium
8/29/2018Morgan StanleyBoost TargetUnderweight ➝ Underweight$36.00 ➝ $46.00High
7/5/2018BarclaysBoost TargetUnderweight ➝ Underweight$31.00 ➝ $33.00Low
5/9/2018Credit Suisse GroupBoost TargetNeutral ➝ Neutral$39.00 ➝ $42.00Low
2/7/2018Morgan StanleyBoost TargetUnderweight ➝ Underweight$30.00 ➝ $36.00Low
2/6/2018Credit Suisse GroupBoost TargetNeutral ➝ Neutral$37.00 ➝ $39.00Medium
11/10/2017Piper Jaffray CompaniesReiterated RatingBuy$42.00N/A
10/6/2017Piper Jaffray CompaniesSet TargetBuy$41.00N/A
8/31/2017Piper Jaffray CompaniesReiterated RatingBuy$42.00 ➝ $41.00Low
8/31/2017Credit Suisse GroupBoost TargetOutperform$36.00 ➝ $37.00High
8/25/2017Piper Jaffray CompaniesSet TargetBuy$42.00Medium
8/23/2017Bank of AmericaReiterated RatingUnderperform ➝ Underperform$33.00High
(Data available from 8/18/2017 forward)

News Sentiment Rating

0.10 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/20/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/19/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/21/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/20/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/20/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/19/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/19/2022
  • 0 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/18/2022

Current Sentiment

  • 0 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Phibro Animal Health logo
Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.
Read More

Today's Range

Now: $18.30
Low: $18.14
High: $18.39

50 Day Range

MA: $19.19
Low: $17.89
High: $20.30

52 Week Range

Now: $18.30
Low: $17.28
High: $26.55

Volume

2,496 shs

Average Volume

85,692 shs

Market Capitalization

$741.15 million

P/E Ratio

12.62

Dividend Yield

2.56%

Beta

0.51

Frequently Asked Questions

What sell-side analysts currently cover shares of Phibro Animal Health?

The following Wall Street research analysts have issued research reports on Phibro Animal Health in the last year: Barclays PLC, Morgan Stanley, StockNews.com, and TheStreet.
View the latest analyst ratings for PAHC.

What is the current price target for Phibro Animal Health?

2 Wall Street analysts have set twelve-month price targets for Phibro Animal Health in the last year. Their average twelve-month price target is $22.50, suggesting a possible upside of 23.5%. Morgan Stanley has the highest price target set, predicting PAHC will reach $23.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $22.00 for Phibro Animal Health in the next year.
View the latest price targets for PAHC.

What is the current consensus analyst rating for Phibro Animal Health?

Phibro Animal Health currently has 1 sell rating and 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PAHC, but not buy more shares or sell existing shares.
View the latest ratings for PAHC.

What other companies compete with Phibro Animal Health?

How do I contact Phibro Animal Health's investor relations team?

Phibro Animal Health's physical mailing address is GLENPOINTE CENTRE EAST 3RD FLOOR 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ, 07666. The company's listed phone number is (201) 329-7300 and its investor relations email address is [email protected] The official website for Phibro Animal Health is www.pahc.com. Learn More about contacing Phibro Animal Health investor relations.